ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Phaxiam Therapeutics

Phaxiam Therapeutics (0QSS)

71,025
0,00
(0,00%)
Geschlossen 07 Januar 5:30PM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
71,025
Gebot
6,925
Fragen
7,28
Volumen
0,00
0,00 Tagesbereich 0,00
71,025 52-Wochen-Bereich 71,025
Marktkapitalisierung
Handelsende
71,025
Handelsbeginn
-
Letzte Trade
(O)
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
5
Ausgegebene Aktien
6.075.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,44
Gewinn pro Aktie (EPS)
-3,87
Erlöse
1,33M
Nettogewinn
-23,49M

Über Phaxiam Therapeutics

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Lyon, Rhone, Fra
Gegründet
-
Phaxiam Therapeutics is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0QSS. The last closing price for Phaxiam Therapeutics was 71,03 €. Over the last year, Phaxiam Therapeutics shares have traded in a share price range of 71,025 € to 71,025 €.

Phaxiam Therapeutics currently has 6.075.000 shares in issue. The market capitalisation of Phaxiam Therapeutics is 431,48 € million. Phaxiam Therapeutics has a price to earnings ratio (PE ratio) of -0.44.

0QSS Neueste Nachrichten

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024 Article 223-16 du Règlement Général de...

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024 Article 223-16 of general regulation of French...

PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie

PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie Tenue d’un webinaire le 27 novembre 2024 « Evolving strategic...

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area Webinar being held today "Evolving strategic context for phages...

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » PHAXIAM a présenté son test IVD Phagogramme et l’actualisation...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility...

PHAXIAM Reports Third-Quarter 2024 Financial Information

PHAXIAM Reports Third-Quarter 2024 Financial Information Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase...

PHAXIAM publie l’information financière du troisième trimestre 2024

PHAXIAM publie l’information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie de 5,7 M€ au 30 septembre 2024Exécution de la stratégie clinique conforme au plan, avec...

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Monthly information related to total number of voting rights and shares...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Information mensuelle relative au nombre total de droits de vote et...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10071.02571.02571.025471.025DE
40071.02571.02571.025171.025DE
120071.02571.02571.025571.025DE
260071.02571.02571.025371.025DE
520071.02571.02571.025371.025DE
1560071.02571.02571.025149471.025DE
2600071.02571.02571.025194571.025DE

0QSS - Frequently Asked Questions (FAQ)

What is the current Phaxiam Therapeutics share price?
The current share price of Phaxiam Therapeutics is 71,025 €
How many Phaxiam Therapeutics shares are in issue?
Phaxiam Therapeutics has 6.075.000 shares in issue
What is the market cap of Phaxiam Therapeutics?
The market capitalisation of Phaxiam Therapeutics is EUR 431,48M
What is the 1 year trading range for Phaxiam Therapeutics share price?
Phaxiam Therapeutics has traded in the range of 71,025 € to 71,025 € during the past year
What is the PE ratio of Phaxiam Therapeutics?
The price to earnings ratio of Phaxiam Therapeutics is -0,44
What is the cash to sales ratio of Phaxiam Therapeutics?
The cash to sales ratio of Phaxiam Therapeutics is 7,83
What is the reporting currency for Phaxiam Therapeutics?
Phaxiam Therapeutics reports financial results in EUR
What is the latest annual turnover for Phaxiam Therapeutics?
The latest annual turnover of Phaxiam Therapeutics is EUR 1,33M
What is the latest annual profit for Phaxiam Therapeutics?
The latest annual profit of Phaxiam Therapeutics is EUR -23,49M
What is the registered address of Phaxiam Therapeutics?
The registered address for Phaxiam Therapeutics is 60 AVENUE ROCKEFELLER, LYON, RHONE, 69008
What is the Phaxiam Therapeutics website address?
The website address for Phaxiam Therapeutics is www.phaxiam.com
Which industry sector does Phaxiam Therapeutics operate in?
Phaxiam Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SCGLSealand Capital Galaxy Limited
3,25p
(103,13%)
12,18M
BORBorders & Southern Petroleum Plc
3,64p
(51,04%)
23,81M
NEONeo Energy Metals Plc
0,95p
(22,58%)
37,84M
GNIPGenip Plc
32,00p
(20,75%)
192,82k
ZIOCZanaga Iron Ore Company Limited
10,50p
(19,86%)
2,84M
DGIDg Innovate Plc
0,02p
(-20,00%)
298,54M
SNGSynairgen Plc
2,10p
(-19,39%)
1,67M
VRSVersarien Plc
0,03p
(-18,92%)
103,72M
QEDQuadrise Plc
5,90p
(-17,83%)
17,66M
ZENZenith Energy Ltd.
4,90p
(-16,24%)
1,48M
SYMESupply@me Capital Plc
0,0042p
(12,00%)
1,19B
MSMNMosman Oil And Gas Limited
0,035p
(12,90%)
654,48M
TRPTower Resources Plc
0,0395p
(0,00%)
570,56M
CPXCap-xx Limited
0,1775p
(-2,74%)
379,2M
NTVONativo Resources Plc
0,0019p
(-5,00%)
312,89M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock